1FGI

CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR

Summary for 1FGI

• Entry DOI: 10.2210/pdb1fgi/pdb
• Descriptor: FGF RECEPTOR 1, 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE (3 entities in total)
• Functional Keywords: protein kinase, transferase, tyrosine-protein kinase, atp-binding, phosphorylation, inhibitor
• Biological source: Homo sapiens (human)
• Cellular location: Membrane; Single-pass type I membrane protein: P11362
• Total number of polymer chains: 2
• Total formula weight: 71209.87

Authors

Mohammadi, M.,Schlessinger, J.,Hubbard, S.R. (deposition date: 1997-03-22, release date: 1998-04-08, Last modification date: 2024-02-07)

Primary citation

Mohammadi, M.,McMahon, G.,Sun, L.,Tang, C.,Hirth, P.,Yeh, B.K.,Hubbard, S.R.,Schlessinger, J.
Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.
Science, 276:955-960, 1997

PubMed Abstract: A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones). Two compounds from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward other receptor tyrosine kinases. Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compounds were determined. The oxindole occupies the site in which the adenine of adenosine triphosphate binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes. The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop. This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.

PubMed: 9139660
DOI: 10.1126/science.276.5314.955

Experimental method

X-RAY DIFFRACTION (2.5 Å)